Silent information regulator 1 protects the brain against cerebral ischemic damage

Stroke

Volumn 44, Issue 8, 2013, Pages 2333-2337

  Hernández Jiménez, MacArena ^a   Hurtado, Olivia ^a   Cuartero, María I ^a   Ballesteros, Iván ^a   Moraga, Ana ^a   Pradillo, Jesús M ^b   McBurney, Michael W ^c,d   Lizasoain, Ignacio ^a   Moro, María A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

neuroprotection; SIRT1; stroke

Indexed keywords

ACTIVATOR 3; ENZYME ACTIVATOR; HISTONE H3; HISTONE H4; PROTEIN P53; SIRTINOL; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; GENE DELETION; HISTONE ACETYLATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; UPREGULATION;

NEUROPROTECTION; SIRT1; STROKE;

ACETYLATION; ALLELES; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BRAIN; BRAIN ISCHEMIA; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION MEDIATORS; MICE; MICE, KNOCKOUT; NF-KAPPA B; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SINGLE-BLIND METHOD; SIRTUIN 1; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84880790329     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001715     Document Type: Article

References (23)

1. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253-295.
2. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtu-ins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11:443-461.
3. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, res-veratrol, and ischemic preconditioning. J Cereb Blood Flow Metab. 2011;31:1003-1019.
4. Donmez G. The neurobiology of sirtuins and their role in neurodegenera-tion. Trends Pharmacol Sci. 2012;33:494-501.
5. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122:2170-2182.
6. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol. 2003;23:38-54. (Pubitemid 36008499)
7. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008;7: 841-853.
8. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6:e19881.
9. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008;28:9989-9996.
10. Michán S, Li Y, Chou MM, Parrella E, Ge H, Long JM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010;30:9695-9707.
11. Calvanese V, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, et al. Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci USA. 2010;107:13736-13741.
12. Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006;26: 1141-1147. (Pubitemid 44268176)
13. Hurtado O, Hernández-Jiménez M, Zarruk JG, Cuartero MI, Ballesteros I, Camarero G, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. April 18, 2013. doi: 10.1111/jnc.12269. Available at: http://onlinelibrary. wiley.com/doi/10.1111/jnc.12269/full. Accessed: May 13, 2013.
14. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacety-lase SIRT1. J Biol Chem. 2007;282:6823-6832. (Pubitemid 47100909)
15. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun. 2005;331:761-777. (Pubitemid 40615507)
16. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198.
17. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293:1653-1657. (Pubitemid 32807844)
18. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001;20:1331-1340. (Pubitemid 32233973)
19. Lanzillotta A, Sarnico I, Ingrassia R, Boroni F, Branca C, Benarese M, et al. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis. 2010; 1:e96.
20. Raz L, Zhang QG, Han D, Dong Y, De Sevilla L, Brann DW. Acetylation of the pro-apoptotic factor, p53 in the hippocampus following cerebral ischemia and modulation by estrogen. PLoS One. 2011;6:e27039.
21. Chen Y, Zhao W, Yang JS, Cheng Z, Luo H, Lu Z, et al. Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol Cell Proteomics. 2012;11:1048-1062.
22. Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007;26:105-111. (Pubitemid 46436490)
23. Diederich K, Frauenknecht K, Minnerup J, Schneider BK, Schmidt A, Altach E, et al. Citicoline enhances neuroregenerative processes after experimental stroke in rats. Stroke. 2012;43:1931-1940.